FATE THERAPEUTICS INC Quarterly Net Cash Provided by (Used in) Financing Activities in USD from Q1 2018 to Q1 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Fate Therapeutics Inc quarterly/annual Net Cash Provided by (Used in) Financing Activities history and growth rate from Q1 2018 to Q1 2024.
  • Fate Therapeutics Inc Net Cash Provided by (Used in) Financing Activities for the quarter ending March 31, 2024 was $95.5M, a 46029% increase year-over-year.
  • Fate Therapeutics Inc annual Net Cash Provided by (Used in) Financing Activities for 2023 was $85K.
  • Fate Therapeutics Inc annual Net Cash Provided by (Used in) Financing Activities for 2022 was $9.21M, a 98% decline from 2021.
  • Fate Therapeutics Inc annual Net Cash Provided by (Used in) Financing Activities for 2021 was $453M, a 60.2% increase from 2020.
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 $95.5M +$95.3M +46029% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q1 2023 $207K -$2.59M -92.6% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q1 2022 $2.8M -$435M -99.4% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-03
Q1 2021 $438M +$437M +30090% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-04
Q1 2020 $1.45M +$193K +15.3% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-05
Q1 2019 $1.26M +$903K +254% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-11
Q1 2018 $355K Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-07
* An asterisk sign (*) next to the value indicates that the value is likely invalid.